All news

Does Early Lung Cancer Trial Data Change The Bull Case For Zai Lab Stock (ZLAB)?

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Zai Lab released promising early global Phase 1b data for zocilurtatug pelitecan with atezolizumab in extensive-stage small cell lung cancer, showing high objective response rates and a manageable safety profile. This clinical update was coupled with a US$250 million private placement to fund a global Phase 3 trial and other late-stage studies.

Read original source

ZLAB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.